/CMMB
CMMB Stock - Chemomab Therapeutics Ltd.
Healthcare|BiotechnologyNASDAQ
$1.89-1.56%
$0.03 (-1.56%) • Dec 19
54
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.98
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.08
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CMMB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.87 – $1.91
TARGET (TP)$2.17
STOP LOSS$1.74
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.55
52W High$9.84
52W Low$1.73
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-53,251 | $-66,827 | $-57,773 | $-34,023 | $-79,999 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-14,739,000 | $-25,459,000 | $-28,533,000 | $-12,367,000 | $-5,972,000 |
| Net Income | $-13,945,000 | $-24,221,000 | $-27,646,000 | $-12,478,000 | $-5,951,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.12 | $-8.22 | $-9.68 | $-4.80 | $-25.21 |
Company Overview
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$6
Average Target
↑ 199.8% Upside
Now
$4
Low
$6
Average
$7
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 13th 2024 | Maxim Group | Initiation | Buy | $4 |
| May 6th 2024 | Oppenheimer | Upgrade | Outperform | $6 |
| December 19th 2023 | ROTH MKM | Resumed | Buy | $7 |
Earnings History & Surprises
CMMBBeat Rate
44%
Last 18 quarters
Avg Surprise
-22.2%
EPS vs Estimate
Beats / Misses
8/8
2 met exactly
Latest EPS
$-0.80
Q4 2025
EPS Surprise History
Q1 24
+35.0%
$-0.26vs$-0.40
Q2 24
-40.0%
$-0.28vs$-0.20
Q3 24
-30.0%
$-0.26vs$-0.20
Q4 24
0.0%
$-0.20vs$-0.20
Q1 25
+20.0%
$-0.16vs$-0.20
Q2 25
+30.0%
$-0.14vs$-0.20
Q3 25
+55.0%
$-0.36vs$-0.80
Q4 25
-300.0%
$-0.80vs$-0.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $-0.20 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.20 | $-0.80 | -300.0% | ✗ MISS |
Q3 2025 | Aug 14, 2025 | $-0.80 | $-0.36 | +55.0% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.20 | $-0.14 | +30.0% | ✓ BEAT |
Q1 2025 | Mar 3, 2025 | $-0.20 | $-0.16 | +20.0% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.20 | $-0.20 | 0.0% | = MET |
Q3 2024 | Aug 21, 2024 | $-0.20 | $-0.26 | -30.0% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.20 | $-0.28 | -40.0% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $-0.40 | $-0.26 | +35.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-0.60 | $-0.34 | +43.3% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.80 | $-0.72 | +10.0% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.80 | $-0.80 | 0.0% | = MET |
Q1 2023 | Mar 20, 2023 | $-0.80 | $-0.72 | +10.0% | ✓ BEAT |
Q4 2022 | Nov 11, 2022 | $-0.60 | $-0.70 | -16.7% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | $-0.60 | $-0.54 | +10.0% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.40 | $-0.44 | -10.0% | ✗ MISS |
Q1 2022 | Mar 9, 2022 | $-0.40 | $-0.44 | -10.0% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | $-0.14 | $-0.26 | -79.3% | ✗ MISS |
Q3 2021 | Aug 13, 2021 | $-0.12 | $-0.26 | -126.1% | ✗ MISS |
Latest News
Chemomab Therapeutics Data From Phase 2 SPRING Study Shows Nebokitug Was Safe, Well Tolerated In Participants With Primary Sclerosing Cholangitis At Up To 48 Weeks Of Treatment
📈 PositiveBenzinga•Dec 2, 2025, 01:16 PM
Chemomab Therapeutics Q3 EPS $(0.28) Beats $(0.40) Estimate
📈 PositiveBenzinga•Nov 20, 2025, 01:30 PM
Chemomab To Present Abstracts Highlighting New Clinical Data From Nebokitug Phase 2 SPRING Trial In Primary Sclerosing Cholangitis, At AASLD 2025
📈 PositiveBenzinga•Nov 6, 2025, 01:09 PM
Oppenheimer Maintains Outperform on Chemomab Therapeutics, Raises Price Target to $25
📈 PositiveBenzinga•Aug 27, 2025, 04:22 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Aug 25, 2025, 11:50 PM
Frequently Asked Questions about CMMB
What is CMMB's current stock price?
Chemomab Therapeutics Ltd. (CMMB) is currently trading at $1.89 per share. The stock has moved -1.56% today.
What is the analyst price target for CMMB?
No analyst price targets are currently available for this stock.
What sector is Chemomab Therapeutics Ltd. in?
Chemomab Therapeutics Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CMMB's market cap?
Chemomab Therapeutics Ltd. has a market capitalization of $0.01 billion, making it a small-cap company.
Does CMMB pay dividends?
No, Chemomab Therapeutics Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBIVI
BioVie Inc.
$1.41
Mkt Cap: $0.0B
CANF
Can-Fite BioPharma Ltd.
$0.25
Mkt Cap: $0.0B
CERO
CERo Therapeutics Holdings, Inc.
$0.10
Mkt Cap: $0.0B
ELAB
PMGC Holdings Inc.
$2.26
Mkt Cap: $0.0B
GLMD
Galmed Pharmaceuticals Ltd.
$0.85
Mkt Cap: $0.0B
INM
InMed Pharmaceuticals Inc.
$1.19
Mkt Cap: $0.0B
KZIA
Kazia Therapeutics Limited
$10.87
Mkt Cap: $0.0B
OCEA
Ocean Biomedical, Inc.
$0.00
Mkt Cap: $0.0B
TOVX
Theriva Biologics, Inc.
$0.19
Mkt Cap: $0.0B
XRTX
XORTX Therapeutics Inc.
$0.60
Mkt Cap: $0.0B
Explore stocks similar to CMMB for comparison